NEURODEGENERATION RESULTING FROM AN INFLAMMATORY CASCADE
Cognitive impairment following stroke affects more than 10 million people worldwide, with an estimated population of 2 million in the U.S., almost 5 million in the EU, and almost 3 million in Japan and China.
Nearly 800,000 people in the U.S. have a stroke every year, the majority of which are ischemic strokes, where a clot blocks a blood vessel and cuts off blood flow and oxygen to the brain. Stroke is a leading cause of long-term disability with few treatment options available to affect the course of disease.
From past research, it’s understood that mast cells are the first responders to the site of ischemia, causing immediate inflammation, the long-term consequences of which are neuronal loss and brain atrophy. Since cromolyn is a mast cell stabilizer with proven anti-inflammatory properties, we are developing our optimized, proprietary formulation of inhaled cromolyn sodium (ALZT-OP1a) for the treatment of post-ischemic stroke cognitive impairment (PSCI).
With an approved IND, we are planning to advance ALZT-OP1a directly into Phase 2 clinical development in PSCI. (See Pipeline for more on the clinical development of ALZT-OP1a.)
FOR MORE ON STROKE AND ACCESS TO PATIENT RESOURCES, PLEASE VISIT: